Ground Zero Pharmaceuticals   Report issue

For profit Phase 2 Phase 4
Founded: Irvine CA United States (1987)

Organization Overview

First Clinical Trial
2008
NCT01302483
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Ground Zero Pharmaceuticals

Active Ingredients

Drugs in Phase 4 Trials (1)

dapagliflozin (farxiga) (1 trial)

Drugs in Phase 2 Trials (3)

lidocaine (xylocaine) (1 trial)

oxymetazoline (ocuclear) (2 trials)

tetracaine (pontocaine) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Renal Insufficiency (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 4